TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06517888: A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma

Sponsor: Eli Lilly and Company · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 27 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,637,325

Rescue Site Savings

+$7,004,000

Unlock Full NCT06517888 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06517888 Rescue Dossier →